


Supplementary material for Kothari et al., Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation, *Acta Oncol*, 2015;54:487–92.



Supplementary Figure 1. Overall survival for aspirin use versus non-use in stage 4 CRC.

Supplementary Table I. Baseline characteristics between cancer centers.

	Total	RMH	Moffitt	p-Value
Number	185	112	73	
Median age (years)	72	74	69	0.038
Median follow-up (months)	54	66	50	0.002
Aspirin				
Aspirin use	49	27	22	30%
Non-use	136	85	51	70%
Primary site				1.00
Right-sided	107	65	42	58%
Left-sided	77	47	30	41%
Unknown	1		1	1%
AJCC Stage				0.001
1	8	0	8	11%
2	66	36	30	41%
3	67	45	22	30%
4	44	31	13	18%

Supplementary Table II. Overall and cancer-specific survival for aspirin use versus non-use at each cancer center.

	Overall survival	Cancer-specific survival
RMH (n = 112)	HR 0.83 (0.45, 1.54), p = 0.56	HR 0.57 (0.29, 1.29), p = 0.20
Moffitt (n = 73)	HR 1.36 (0.56, 3.33), p = 0.50	HR 0.67 (0.23, 1.95), p = 0.48

Supplementary Table III. Baseline characteristics of PIK3CA exon 9 and 20 mutation patients comparing aspirin use to non-use.

	Total	Aspirin use		Aspirin non-use		p-Value
Number	152	39		113		
Median age (years)	72	74		70		
Median follow-up (months)	59	64		59		0.12
Cancer center						
RMH	112	27	69%	85	75%	0.53
Moffitt	40	22	31%	28	25%	
Primary site						0.003
Right-sided	86	14	36%	72	64%	
Left-sided	65	25	64%	40	35%	
Unknown	1	0		1	1%	
AJCC Stage						
1	2	0	0%	2	2%	
2	53	11	28%	42	37%	0.11
3	58	21	54%	37	33%	
4	39	7	18%	32	28%	

Supplementary Table IV. Univariate and multivariate overall and cancer-specific survival analyses for exon 9 and 20 PIK3CA mutant patients only.

	Overall survival					
	Univariate			Multivariate		
	HR	95% CI	p-Value	HR	95% CI	p-Value
Aspirin use	0.93	0.54, 1.60	0.79	1.01	0.54, 1.86	0.97
Age (decades)	1.47	1.15, 1.87	0.0002	1.45	1.10, 1.90	0.009
Stage						
1/2	1			1		
3	2.05	1.05, 4.02	0.036	2.37	1.19, 4.71	0.014
4	4.39	2.27, 8.48	<0.001	4.83	2.46, 9.49	<0.001
Cancer center (Moffitt referent)	1.77	0.94, 3.31	0.076	1.34	0.70, 2.57	0.38
Primary site (right referent)	0.63	0.38, 1.05	0.076	0.54	0.31, 0.94	0.03
	Cancer-specific survival					
	Univariate			Multivariate		
	HR	95% CI	p-Value	HR	95% CI	p-Value
Aspirin use	0.58	0.32, 1.19	0.16	0.84	0.36, 1.97	0.68
Age (decades)	1.12	0.86, 1.47	0.40	1.00	0.72, 1.39	0.99
Stage						
1/2	1			1		
3	2.34	0.81, 6.76	0.115	2.65	0.91, 7.73	0.075
4	11.13	4.29, 28.87	<0.001	12.52	4.75, 33.00	<0.001
Cancer center (Moffitt referent)	1.73	0.80, 3.74	0.16	1.51	0.67, 3.41	0.32
Primary site (right referent)	0.63	0.34, 1.16	0.14	0.49	0.25, 0.97	0.042

Supplementary Table V. Overall, cancer-specific and recurrence-free survival – aspirin use versus non-use for exon 9 and 20 PIK3CA mutant patients only (per stage).

	Overall survival			Cancer-specific survival			Recurrence-free survival		
	HR	95% CI	p-Value	HR	95% CI	p-Value	HR	95% CI	p-Value
Stage 2 (n = 64)	1.69	0.52, 5.50	0.38	0.94	0.10, 8.42	0.96	1.29	0.26, 6.38	0.76
Stage 3 (n = 66)	1.28	0.57, 2.85	0.54	1.10	0.32, 3.79	0.87	0.80	0.27, 2.40	0.70
Stage 4 (n = 44)	0.36	0.10, 1.25	0.10	0.36	0.10, 1.25	0.10	–	–	–